Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Advanced breast cancer
Chemotherapy
Endocrine therapy
HR+/HER2−
Progression-free survival
Real-word data
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
26
06
2021
accepted:
06
09
2021
pubmed:
24
10
2021
medline:
18
1
2022
entrez:
23
10
2021
Statut:
ppublish
Résumé
A major question when treating HR+/HER2- metastatic breast cancer (MBC) is whether early introduction of chemotherapy (CT) increases endocrine resistance. We aimed to describe progression-free survival (PFS) under first endocrine therapy (ET) depending on whether given before or after CT in a large nationwide cohort, in the pre-CDK era. The real-life retrospective ESME database includes all patients with MBC whose first-line treatment was initiated between 2008 and 2014 in one of the 18 French Comprehensive Cancer Centres. Our primary objective was to compare PFS from start of first ET in patients with HR+/HER2- MBC who received ET or CT first. We identified 6293 patients who received at least one ET line during their first two therapeutic lines for MBC. As first-line therapy, 3832 (60.9%) received ET alone (ET1 1st group), whilst 2461 (39.1%) received CT, including 2024 patients (32.2%) with maintenance ET after CT (ET1 after CT group). Median PFS under first ET was 12.4 months (95% CI 11.9-13.1) in ET 1st group vs. 12.6 months in ET1 after CT group (95% CI 12.1-13.4), HR 0.96 (95% CI 0.90-1.01, P = 0.1277). PFS under first ET appears identical whether prescribed before or after chemotherapy. These data suggest chemotherapy does not promote endocrine resistance.
Identifiants
pubmed: 34687411
doi: 10.1007/s10549-021-06382-6
pii: 10.1007/s10549-021-06382-6
doi:
Substances chimiques
Hormones
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
191-207Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ghoncheh M, Pournamdar Z, Salehiniya H (2016) Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 17(S3):43–46
doi: 10.7314/APJCP.2016.17.S3.43
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M et al (2018) Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 1(103):356–387
doi: 10.1016/j.ejca.2018.07.005
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI. https://doi.org/10.1093/jnci/dju055
doi: 10.1093/jnci/dju055
pubmed: 24777111
pmcid: 4580552
Cortesi L, Toss A, Cirilli C, Marcheselli L, Braghiroli B, Sebastiani F et al (2015) Twenty-years experience with de novo metastatic breast cancer. Int J Cancer 137(6):1417–1426
doi: 10.1002/ijc.29503
Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E et al (1990) Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. Eur J Cancer Oxf Engl 2020(129):60–70
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F et al (2018) 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol 29(8):1634–1657
doi: 10.1093/annonc/mdy192
Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD et al (2014) Breast cancer version 3.2014. J Natl Compr Cancer Netw 12(4):542–90
doi: 10.6004/jnccn.2014.0058
Wilcken N, Hornbuckle J, Ghersi D (2003) Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2021:CD002747
Jacquet E, Lardy-Cléaud A, Pistilli B, Franck S, Cottu P, Delaloge S et al (1990) Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer Oxf Engl 2018(95):93–101
Bonotto M, Gerratana L, Di Maio M, De Angelis C, Cinausero M, Moroso S et al (2017) Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis. Breast Edinb Scotl 31:114–120
doi: 10.1016/j.breast.2016.10.021
Le Saux O, Lardy-Cleaud A, Frank S, Debled M, Cottu PH, Pistilli B et al (2019) Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. Eur J Cancer Oxf Engl 1990(118):131–141
doi: 10.1016/j.ejca.2019.06.014
Lobbezoo DJA, van Kampen RJW, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ et al (2016) In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol Off J Eur Soc Med Oncol 27(2):256–262
doi: 10.1093/annonc/mdv544
Watanabe J, Hayashi T, Tadokoro Y, Nishimura S, Takahashi K (2017) Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution. Breast Cancer Res Treat 166(3):911–917
doi: 10.1007/s10549-017-4478-z
Kim HK, Lee S-H, Kim YJ, Park SE, Lee HS, Lim SW et al (2019) Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea. BMC Cancer 19(1):84
doi: 10.1186/s12885-018-5258-9
Walbaum B, Acevedo F, Medina L, Bravo ML, Merino T, Camus M et al (2020) First-line endocrine therapy for advanced breast cancer. a real-world study at a Latin American university health institution. Curr Med Res Opin 36:1195–1199
doi: 10.1080/03007995.2020.1763282
UNICANCER—Key figures [Internet]. [cited 2021 May 9]. http://www.unicancer.fr/en/unicancer-group/key-figures
Pérol M, Carton M, Debieuvre D, Quantin X, Girard N, Audigier-Vallette C et al (2021) Programme épidémio-stratégie médicoéconomique: une base nationale de données de vie réelle pour mieux comprendre la prise en charge du cancer bronchopulmonaire en France. Rev Mal Respir Actual 13(1):121
Romeo C, Meeus P, Rodrigues M, Leblanc E, Floquet A, Pautier P et al (2019) EP967 Natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment. Int J Gynecol Cancer. https://doi.org/10.1136/ijgc-2019-ESGO.1013
doi: 10.1136/ijgc-2019-ESGO.1013
Pérol D, Robain M, Arveux P, Mathoulin-Pélissier S, Chamorey E, Asselain B et al (2019) The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the epidemiological strategy and medical economics (ESME). BMJ Open 9(2):e023568
doi: 10.1136/bmjopen-2018-023568
Public Policy Committee, International Society of Pharmacoepidemiology (2016) Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf 25(1):2–10
doi: 10.1002/pds.3891
ADELF, ADEREST, AEEMA, EPITER (2008) Recommendations for professional standards and good epidemiological practices (version France 2007). Rev Epidemiol Sante Publique 56:S121–S175
doi: 10.1016/j.respe.2008.05.001
Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936
doi: 10.1056/NEJMoa1607303
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S et al (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol Off J Eur Soc Med Oncol 29(7):1541–1547
doi: 10.1093/annonc/mdy155
Tripathy D, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N et al (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19(7):904–915
doi: 10.1016/S1470-2045(18)30292-4
Johnston S, Martin M, Di Leo A, Im S-A, Awada A, Forrester T et al (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5:5
doi: 10.1038/s41523-018-0097-z
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S-A, Masuda N et al (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17(4):425–439
doi: 10.1016/S1470-2045(15)00613-0